A Phase 1 interventional study of methylprednisolone and methylprednisolone in Biological Availability, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-28.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: methylprednisolone
Drug: methylprednisolone
Drug: methylprednisolone
powder for oral suspension 4 mg/mL single dose (8 mL)
powder for oral suspension 4 mg/mL singe dose (8 ml)
tablet 32 mg single dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hours (hrs) post-dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose
Plasma Decay Half-life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose
| Milestone | Methylprednisolone 32 mg Tablet, Formulation 1, Formulation 2 | Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1 | Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2 | Methylprednisolone Formulation 1, Formulation 2, 32 mg Tablet | Methylprednisolone Formulation 2, 32 mg Tablet, Formulation 1 | Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 3 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Methylprednisolone 32 mg Tablet, Formulation 1, Formulation 2 | Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1 | Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2 | Methylprednisolone Formulation 1, Formulation 2, 32 mg Tablet | Methylprednisolone Formulation 2, 32 mg Tablet, Formulation 1 | Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 4 | 4 | 4 |
| Completed | 3 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Methylprednisolone 32 mg Tablet, Formulation 1, Formulation 2 | Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1 | Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2 | Methylprednisolone Formulation 1, Formulation 2, 32 mg Tablet | Methylprednisolone Formulation 2, 32 mg Tablet, Formulation 1 | Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 4 | 4 | 4 | 4 |
| Completed | 3 | 3 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Methylprednisolone 32 mg Tablet, Formulation 1, Formulation 2 | Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1 | Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2 | Methylprednisolone Formulation 1, Formulation 2, 32 mg Tablet | Methylprednisolone Formulation 2, 32 mg Tablet, Formulation 1 | Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 4 | 4 | 4 |
| Completed | 3 | 3 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Methylprednisolone 32 mg Tablet, Formulation 1, Formulation 2 | Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1 | Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2 | Methylprednisolone Formulation 1, Formulation 2, 32 mg Tablet | Methylprednisolone Formulation 2, 32 mg Tablet, Formulation 1 | Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 4 | 4 | 4 |
| Completed | 3 | 3 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | Methylprednisolone 32 mg Tablet | Methylprednisolone 32 mg Micronized API | Methylprednisolone 32 mg Sieve Cut API |
|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 1286.00 ± 385.27 | 1204.00 ± 394.65 | 1180.00 ± 355.26 |
| ng/mL | Methylprednisolone 32 mg Tablet | Methylprednisolone 32 mg Micronized API | Methylprednisolone 32 mg Sieve Cut API |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 289.00 ± 60.42 | 279.10 ± 82.91 | 246.20 ± 66.05 |
| hr | Methylprednisolone 32 mg Tablet | Methylprednisolone 32 mg Micronized API | Methylprednisolone 32 mg Sieve Cut API |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 2.00 (1.00 to 4.00) | 1.00 (0.50 to 4.00) | 2.00 (1.00 to 3.00) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Methylprednisolone 32 mg Tablet | Methylprednisolone 32 mg Micronized API | Methylprednisolone 32 mg Sieve Cut API |
|---|---|---|---|
| Plasma Decay Half-life (t1/2) | 2.43 ± 0.39 | 2.42 ± 0.37 | 2.45 ± 0.35 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methylprednisolone 32 mg Tablet | — | 0/24 (0%) | 4/24 (16.7%) |
| Methylprednisolone 32 mg Micronized API | — | 0/22 (0%) | 0/22 (0%) |
| Methylprednisolone 32 mg Sieve Cut API | — | 0/23 (0%) | 1/23 (4.3%) |
| Event | Methylprednisolone 32 mg Tablet | Methylprednisolone 32 mg Micronized API | Methylprednisolone 32 mg Sieve Cut API |
|---|---|---|---|
| HeadacheNervous system disorders | 3/24 | 0/22 | 0/23 |
| PhlebitisVascular disorders | 0/24 | 0/22 | 1/23 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/24 | 0/22 | 0/23 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/24 | 0/22 | 0/23 |
| ParaesthesiaNervous system disorders | 1/24 | 0/22 | 0/23 |
| Age Continuous(Years) | Entire Study Population |
|---|---|
| Mean | 32.5 ± 7.9 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 2 |
| Male | 22 |
The record gives a start of Nov 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone